Earlier in March 2026, CRISPR Therapeutics completed a US$550 million private offering of 1.7308% Convertible Senior Unsecured Notes due March 1, 2031, issued under Rule 144A to bolster its funding ...

Wolfspeed, Inc. (NYSE: WOLF) ("Wolfspeed") today announced that on March 19, 2026, it entered into separate, privately ...

The Nevada-focused gold miner said Thursday it plans to offer $250 million of convertible senior notes due 2031, or up to $287.5 million if an option granted to initial purchasers to buy additional ...

Nebius Group (NBIS) announced on Wednesday that it has priced an upsized, $4B private offering of convertible senior notes. Shares were fractionally higher in premarket trading. The $4B note offering ...

I-80 Gold is selling $200 million of convertible bonds to help advance the miner's five gold projects, refurbish a processing plant and fund the expansion of its resource base. The Nevada-focused gold ...

indie Semiconductor, Inc. (NASDAQ:INDI) is included in our list of the 11 most oversold semiconductor stocks to buy now. Positive analyst sentiment continues to surround indie Semiconductor, Inc.

Nebius has launched a private offering of $4 billion in convertible senior notes. The neocloud revealed the size of the offering yesterday (March 18). It will be split into two tranches: $2.25bn of ...

Calgary, Alberta / October 15, 2025 –TheNewswire -Credissential Inc. (“Credissential” or the “Company”) (CSE: WHIP), a vertically integrated AI software development companyis pleased to announce a non ...

Duke Energy Corp. (NYSE:DUK) is one of the 10 best regulated electric stocks to buy according to hedge funds. On March 9, ...

CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday morning. Piper Sandler, ...

Convertible notes are agreements where investors lend money to a company, with the expectation that the loan will convert into equity at a later date, usually during the next significant financing ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to ...